DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. DMDRP Research Highlights/News
  3. FY17 Defense Medical Research and Development Program

NEWS RELEASE

Released: November 10, 2015

Defense Health Program
Defense Medical Research and Development Program
Military Infectious Diseases Research Program
Upcoming Funding Opportunities

The Fiscal Year 2017 (FY17) Joint Program Committee 2 (JPC-2)/Military Infectious Diseases Research Program (MIDRP) is funded with Defense Health Program appropriations through the Defense Health Agency, Research, Development, and Acquisition Directorate to support targeted research efforts to ensure the health and readiness of our military forces. Program announcements will be administered by the US Army Medical Research Acquisition Activity. The Congressionally Directed Medical Research Programs (CDMRP) Defense Medical Research and Development Program (DMRDP) will be the managing agent for program announcements and subsequent awards, with strategic oversight from JPC-2/MIDRP.

The DMRDP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY17 DMRDP JPC-2/MIDRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in December 2015. Pre-application and application deadlines will be available when the program announcements are released. This pre-announcement should not be construed as an obligation by the government.

The FY17 JPC-2/MIDRP is seeking research focused on combat-related or trauma-induced wound infection, specifically involving the following areas. Additional information regarding focus areas will be available when the program announcements are released.

Applied Research:

  • Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs) and nosocomial pathogens, and/or characterization of antimicrobial resistance patterns.
  • Development of assays for host immune response biomarkers for diagnosis or prognosis.
  • Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation.

Clinical Trials/Testing:

  • Evaluation of optimum preventive or directive therapies for combat-related or trauma-induced wound infections using Food and Drug Administration-approved drugs, biologics, or devices either alone or in combination.
  • Evaluation of a functional prototype device or assay for the rapid detection of pathogens and/or microbial drug resistance markers.
  • Evaluation of a functional prototype device or assay for the rapid detection of novel and specific in vivo or in vitro biomarkers (from wound, serum, saliva, or urine) that predict development of infection or discriminate between infection and colonization.

Award Mechanism Eligibility Key Mechanism Elements Funding
Military Infectious Diseases Applied Research Award (MID-ARA) Independent investigators at all academic levels (or equivalent). Both intramural and extramural investigators are encouraged to apply.
  • A pre-application is required
  • The FY17 MID-ARA intent is to support hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models, concept refinement, product candidate evaluation, maturation and/or down-selection, or completion of studies in support of IND/IDE applications.
  • The anticipated funding limit is $2.0M total costs.
  • The anticipated maximum period of performance is 3 years.
Military Infectious Diseases Clinical Trial Award (MID-CTA) Independent investigators at all academic levels (or equivalent). Both intramural and extramural investigators are encouraged to apply.
  • A pre-application is required
  • The FY17 MID-CTA intent is to support early phase clinical trials and medical device (including diagnostics) testing with the potential to have a major impact on prevention and treatment of combat-related or trauma induced wound infections.
  • The anticipated funding limit is $2.5M total costs.
  • The anticipated maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from Grants.gov. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcement release may be sent to help@eBRAP.org. For more information about other CDMRP administered programs, please visit the CDMRP website (https://CDMRP.HEALTH.MIL).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil